Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Merck & Co. Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Loans payable and current portion of long-term debt 2,649 3,149 3,071 3,077 1,372 887 2,839 2,672 1,946 1,936 2,979 1,208 2,412 3,534 2,488 7,251 6,431 2,420 4,718 6,361
Trade accounts payable 4,079 3,586 3,519 3,514 3,922 3,509 3,442 3,680 4,264 3,371 3,482 3,715 4,609 3,366 3,897 4,034 4,594 3,744 3,448 3,572
Accrued and other current liabilities 15,694 16,539 14,712 14,102 15,766 14,840 13,747 13,000 14,159 14,222 13,501 14,051 13,859 14,214 12,888 11,911 13,053 11,690 11,182 10,932
Income taxes payable 3,914 4,330 2,777 2,398 2,649 1,981 1,489 1,872 1,986 1,698 1,438 1,571 1,224 954 971 1,490 1,575 984 1,266 1,033
Dividends payable 2,084 1,982 1,981 2,008 1,985 1,877 1,877 1,907 1,884 1,771 1,768 1,771 1,768 1,660 1,662 1,675 1,674 1,567 1,564 1,585
Current liabilities 28,420 29,586 26,060 25,099 25,694 23,094 23,394 23,131 24,239 22,998 23,168 22,316 23,872 23,728 21,906 26,361 27,327 20,405 22,178 23,483
Long-term debt, excluding current portion 34,462 34,982 34,717 31,142 33,683 33,972 34,072 28,074 28,745 28,482 28,684 30,586 30,690 22,907 24,033 24,002 25,360 26,321 26,156 21,637
Deferred income taxes 1,387 864 876 922 871 1,018 996 1,442 1,795 2,417 2,974 3,071 3,441 1,527 1,489 1,204 1,015 1,777 2,091 1,943
Other noncurrent liabilities 6,465 7,540 7,329 8,262 8,792 7,343 7,265 8,244 8,323 8,660 8,951 9,742 9,434 9,469 9,872 12,241 12,482 12,027 12,446 11,550
Noncurrent liabilities 42,314 43,386 42,922 40,326 43,346 42,333 42,333 37,760 38,863 39,559 40,609 43,399 43,565 33,903 35,394 37,447 38,857 40,125 40,693 35,130
Total liabilities 70,734 72,972 68,982 65,425 69,040 65,427 65,727 60,891 63,102 62,557 63,777 65,715 67,437 57,631 57,300 63,808 66,184 60,530 62,871 58,613
Common stock, $0.50 par value 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788
Other paid-in capital 44,704 44,530 44,362 44,598 44,509 44,358 44,219 44,467 44,379 44,243 44,115 44,275 44,238 44,149 44,039 39,613 39,588 39,489 39,373 39,697
Retained earnings 63,069 61,384 60,187 56,697 53,895 57,082 54,198 62,039 61,081 59,928 58,437 56,252 53,696 51,691 48,777 48,888 47,362 51,107 49,724 48,272
Accumulated other comprehensive loss (4,945) (5,371) (5,361) (5,274) (5,161) (4,916) (4,900) (4,883) (4,768) (4,743) (4,327) (4,369) (4,429) (4,590) (4,628) (6,622) (6,634) (6,383) (6,393) (6,391)
Treasury stock, at cost (58,303) (57,829) (57,394) (57,445) (57,450) (57,066) (56,612) (56,577) (56,489) (56,758) (56,770) (57,063) (57,109) (57,244) (56,682) (56,722) (56,787) (56,815) (56,850) (57,161)
Total Merck & Co., Inc. stockholders’ equity 46,313 44,502 43,582 40,364 37,581 41,246 38,693 46,834 45,991 44,458 43,243 40,883 38,184 35,794 33,294 26,945 25,317 29,186 27,642 26,205
Noncontrolling interests 59 58 66 60 54 54 49 71 67 66 75 70 73 69 94 94 87 84 102 95
Total equity 46,372 44,560 43,648 40,424 37,635 41,300 38,742 46,905 46,058 44,524 43,318 40,953 38,257 35,863 33,388 27,039 25,404 29,270 27,744 26,300
Total liabilities and equity 117,106 117,532 112,630 105,849 106,675 106,727 104,469 107,796 109,160 107,081 107,095 106,668 105,694 93,494 90,688 90,847 91,588 89,800 90,615 84,913

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Merck & Co. Inc. current liabilities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Merck & Co. Inc. noncurrent liabilities increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Merck & Co. Inc. total liabilities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Total Merck & Co., Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Merck & Co. Inc. total Merck & Co., Inc. stockholders’ equity increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.